Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Ipsen Appoints Stewart Campbell Executive Vice President and President of North America: https://mms.businesswire.com/media/20191104006077/en/745053/5/1280px-Ipsen_logo.svg.jpg
Ipsen Appoints Stewart Campbell Executive Vice President and President of North America


Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Stewart Campbell as Executive Vice President and President of North America, effective immediately. Based in Cambridge, he will

BusinessWire_EN 
0 03.11.21
Ipsen erweitert seine präklinische Forschungs- und Entwicklungspipeline für Onkologie im Rahmen einer exklusiven weltweiten Zusammenarbeit mit Accent Therapeutics um ein weiteres Programm mit Fokus auf das RNA-modifizierende Protein METTL3 : https://mms.businesswire.com/media/20191104006077/en/745053/5/1280px-Ipsen_logo.svg.jpg
Ipsen erweitert seine präklinische Forschungs- und Entwicklungspipeline für Onkologie im Rahmen einer exklusiven weltweiten Zusammenarbeit mit Accent Therapeutics um ein weiteres Programm mit Fokus auf das RNA-modifizierende Protein METTL3


Haftungsausschluss: Nur für internationale Medien und Investoren bestimmt



Ipsen (Euronext: IPN; ADR: IPSEY) und Accent Therapeutics (Accent) haben eine exklusive weltweite

BusinessWire_DE 
0 18.10.21
Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3: https://mms.businesswire.com/media/20191104006077/en/745053/5/1280px-Ipsen_logo.svg.jpg
Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3


Regulatory News:



Disclaimer: Intended for international media and investor audiences only



Ipsen (Euronext: IPN; ADR: IPSEY) and Accent Therapeutics (Accent) have signed an exclusive

BusinessWire_EN 
0 18.10.21
ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial
ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial


Regulatory News:



Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in

BusinessWire_EN 
0 19.09.20
Ipsen to Present Results From MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP), at ASBMR 2020 Annual Meeting
Ipsen to Present Results From MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP), at ASBMR 2020 Annual Meeting


Ipsen (Euronext: IPN; ADR: IPSEY) today announced results from the MOVE trial, the first and only multicenter Phase III study in fibrodysplasia ossificans progressiva (FOP), to be presented during

BusinessWire_EN 
0 25.08.20
Ipsen presents Phase I/II clinical data evaluating liposomal irinotecan (Onivyde®) as an investigational first-line combination treatment for metastatic pancreatic cancer at the ESMO World Congress on Gastrointestinal Cancer
Ipsen presents Phase I/II clinical data evaluating liposomal irinotecan (Onivyde®) as an investigational first-line combination treatment for metastatic pancreatic cancer at the ESMO World Congress on Gastrointestinal Cancer


Ipsen (Euronext: IPN; ADR: IPSEY), today announced the primary analysis of the Phase I/II study evaluating the investigational use of irinotecan liposome injection (Onivyde®) in combination with

BusinessWire_EN 
0 01.07.20
Ipsen Announces Publication of First Matching-Adjusted Indirect Comparison of Cabometyx® (cabozantinib) Versus regorafenib in Advanced Hepatocellular Carcinoma in Advances in Therapy
Ipsen Announces Publication of First Matching-Adjusted Indirect Comparison of Cabometyx® (cabozantinib) Versus regorafenib in Advanced Hepatocellular Carcinoma in Advances in Therapy


Regulatory News:



Ipsen (Euronext: IPN; ADR: IPSEY) today announced that data from the matching-adjusted indirect comparison (MAIC) of Cabometyx® (cabozantinib) versus Stivarga® (regorafenib) for

BusinessWire_EN 
0 19.05.20
Ipsen Provides Update on Palovarotene Clinical Programs
Ipsen Provides Update on Palovarotene Clinical Programs


Regulatory News:



Ipsen (Euronext: IPN; ADR: IPSEY) announced today it will begin to reinitiate palovarotene dosing in patients 14 years of age and older currently participating in its

BusinessWire_EN 
0 26.03.20
Ipsen Appoints Steven Hildemann, MD., PhD as Executive Vice President, Chief Medical Officer
Ipsen Appoints Steven Hildemann, MD., PhD as Executive Vice President, Chief Medical Officer


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200113005846/en/



(Photo: Business Wire)




Ipsen (Euronext: IPN; ADR

BusinessWire_EN 
0 14.01.20
Ipsen Appoints Howard Mayer, M.D. as Executive Vice President and Head of Research and Development
Ipsen Appoints Howard Mayer, M.D. as Executive Vice President and Head of Research and Development


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191104006077/en/



Dr. Howard Mayer, Executive Vice-President and Head


BusinessWire_EN 
0 08.11.19
3 High-Yield Dividend Stocks to Buy in 2018
3 High-Yield Dividend Stocks to Buy in 2018
Dividend investors on the hunt for above average income opportunities may want to place a heavy emphasis on pharmaceutical stocks next year. Despite the political turmoil surrounding the....
TheMotleyFool 
0 11.12.17
Novavax Stock Upgraded: 3 Things You Need to Know
Novavax Stock Upgraded: 3 Things You Need to Know
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one....
TheMotleyFool 
0 31.10.17
Is Regeneron Pharmaceuticals, Inc. Stock a Buy?
Is Regeneron Pharmaceuticals, Inc. Stock a Buy?
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stock has been a huge winner in the past. A $10,000 investment in the biotech 10 years ago would be worth more than $200,000 today. Regeneron's....
TheMotleyFool 
0 24.10.17
Should You Buy the Dip With MannKind Stock?
Should You Buy the Dip With MannKind Stock?
You knew it was coming. It was inevitable that MannKind (NASDAQ: MNKD) stock's red-hot momentum would come to an end. The biotech's share price more than tripled in less than two weeks. However,....
TheMotleyFool 
0 12.10.17
Is MannKind Corp Finally a Buy?
Is MannKind Corp Finally a Buy?
MannKind Corporation (NASDAQ: MNKD) shares are up over 175% this month, and that's got anyone who's been paying attention to this troubled biotech wondering, "Can I still buy?" The company's....
TheMotleyFool 
0 11.10.17
3 High-Yield Healthcare Stocks
3 High-Yield Healthcare Stocks
Picking solid high-yield dividend stocks can be tricky. Most companies that offer an elevated yield, after all, tend to do so because of a fundamental weakness in their underlying business. Our....
TheMotleyFool 
0 08.10.17
Here's Why Alnylam Pharmaceuticals Rallied 32.7% in September
Here's Why Alnylam Pharmaceuticals Rallied 32.7% in September
Powered by encouraging phase 3 results for an important pipeline drug, shares of clinical-stage biotech Alnlyam Pharmaceuticals (NASDAQ: ALNY) , which focuses on RNAi treatments, gained 33% in....
TheMotleyFool 
0 05.10.17
Why Regeneron Pharmaceuticals Dropped 11.3% in September
Why Regeneron Pharmaceuticals Dropped 11.3% in September
Despite sharing a series of positive news items with investors, shares of biotech-giant Regeneron Pharmaceuticals (NASDAQ: REGN) fell more than 11% in September, according to data from S&P....
TheMotleyFool 
0 05.10.17
3 High-Yield International Stocks
3 High-Yield International Stocks
Most investors fail to look beyond their home country's borders for investment opportunities. That's a shame because great businesses can be found all around the world.Want proof? We asked a team....
TheMotleyFool 
0 03.10.17
5 Numbers That Should Get MannKind Investors Excited
5 Numbers That Should Get MannKind Investors Excited
MannKind (NASDAQ: MNKD) hasn't exactly given investors a whole lot to get excited about in recent years. That could be changing, though. Since May, MannKind stock has soared more than 130% and now....
TheMotleyFool 
0 26.09.17
Why Novavax, Inc. Could Be a Gold Mine for Growth Investors
Why Novavax, Inc. Could Be a Gold Mine for Growth Investors
If you had the misfortune to buy Novavax (NASDAQ: NVAX) stock in July 2015 and held on, around 90% of your investment would have been wiped out. Ouch. Even if you had bought the biotech stock at....
TheMotleyFool 
0 23.09.17
3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher?
3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher?
One great thing about the biotech industry is that there are nearly always some winners. Regardless of what's going on in the world or in the broader market, at least a few biotech stocks are....
TheMotleyFool 
0 23.09.17
Alnylam Notches a Game-Changing RNAi Win
Alnylam Notches a Game-Changing RNAi Win
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is researching therapies that can treat genetic diseases by interfering with gene expression. Though Alnylam has yet to validate its approach with a....
TheMotleyFool 
0 20.09.17
Gilead Sciences' Kite Pharma Deal Has Already Paid for Itself -- for Investors
Gilead Sciences' Kite Pharma Deal Has Already Paid for Itself -- for Investors
The year 2021 -- that's when Gilead Sciences (NASDAQ: GILD) thinks its acquisition of Kite Pharma (NASDAQ: KITE) will start to pay off. When Gilead announced plans to buy Kite, the company stated....
TheMotleyFool 
0 19.09.17
Why Lexicon Pharmaceuticals Is Down 11% Today
Why Lexicon Pharmaceuticals Is Down 11% Today
After Lexicon Pharmaceuticals (NASDAQ: LXRX) announced yesterday the publication of phase 3 results for its lead diabetes drug, sotagliflozin, in the New England Journal of Medicine, its shares....
TheMotleyFool 
0 14.09.17